Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 15/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971777 | 0.85 | GRM4 (1.00) | GRM4CYP2C9GRM1 | |
| SCHEMBL1899539 | 0.85 | GRM4 (0.79) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL1972220 | 0.84 | GRM4 (0.82) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL1902023 | 0.84 | GRM4 (0.73) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL1897953 | 0.84 | GRM4 (0.73) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL1513878 | 0.84 | GRM4 (0.72) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL6914151 | 0.84 | GRM4 (0.72) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL1899283 | 0.83 | GRM4 (1.00) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL1900749 | 0.83 | GRM4 (0.78) | GRM4CYP1A2CYP2C9CYP2C19GRM1 | |
| SCHEMBL1895474 | 0.83 | GRM1 (0.72) | GRM4CYP1A2CYP2C9CYP2C19GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759377-B2 | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759377-B2 | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759377-B2 | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-05-26 | — | — | US | disclosed |
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-05-26 | — | — | US | disclosed |
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124663-A1 | SUBSTITUTED DIOXOPIPERIDINES AND DIOXOPYRROLIDINES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM4, GRIA4, GRIK4 | GRM4 1/4885CYP1A2 2576/4885CYP2C9 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.